Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.57 |
| ▸ | HTR3B | O95264 | 4/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459324 | 0.93 | CHRNA7 (0.64) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1458636 | 0.92 | HTR3A (0.66) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459350 | 0.84 | CHRNA7 (0.67) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459684 | 0.84 | HTR3A (0.69) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459352 | 0.79 | HTR3A (0.57) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459742 | 0.78 | HTR3A (0.67) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL2229770 | 0.78 | CHRNA7 (0.66) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL2229779 | 0.78 | CHRNA7 (0.66) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL5264415 | 0.78 | HTR3A (0.61) | HTR3A | |
| SCHEMBL6631146 | 0.78 | CHRNA7 (0.60) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2019-02-07 | — | — | US | claimed |
| US-20160214975-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-07-28 | — | — | US | claimed |
| US-20130144062-A1 | HETEROARYL CARBOXAMIDES | Bayer Pharma AG (DE) | 2013-06-06 | — | — | US | claimed |
| US-8227598-B2 | Heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-24 | — | — | US | claimed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| EP-1448530-B1 | HETEROARYL CARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-10-03 | — | — | EP | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-20050209236-A1 | Heteroaryl carboxylic acid amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144062-A1 | HETEROARYL CARBOXAMIDES | GRIN2A, GRIN2C, CNR2 | HTR3A 318/4885CHRNA7 41/4885HTR3E 322/4885 |
| US-20160214975-A1 | HETEROARYL CARBOXAMIDES | GRIN2A, GRIN2C, CNR2 | HTR3A 318/4885CHRNA7 41/4885HTR3E 322/4885 |
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | CNR2, GRIN2A, CNR1 | HTR3A 194/4885CHRNA7 52/4885HTR3E 252/4885 |
| US-20050209236-A1 | Heteroaryl carboxylic acid amides | HCAR2, HCAR1, HCAR3 | HTR3A 536/4885CHRNA7 153/4885HTR3E 1131/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | HTR3A 131/4885CHRNA7 1/4885HTR3E 200/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | HTR3A 131/4885CHRNA7 1/4885HTR3E 200/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 151/4885CHRNA7 1/4885HTR3E 416/4885 |
| US-20080009624-A1 | Heteroaryl carboxamides | GRIN2A, GRIN2C, CNR2 | HTR3A 318/4885CHRNA7 41/4885HTR3E 322/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | HTR3A 112/4885CHRNA7 1/4885HTR3E 177/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 151/4885CHRNA7 1/4885HTR3E 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.